Evidence map›Paper›PMID 30670511›Full record

ArticleBMJ open2019

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.

Radboud J Duintjer Tebbens, Ousmane M Diop, Mark A Pallansch, M Steven Oberste, Kimberly M Thompson

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Disease Surveillance Investments and Administration: Limits to Information Value in Pakistan Polio Eradication.Risk analysis : an official publication of the Society for Risk Analysis · 2021
    Article
  8. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Radboud J Duintjer TebbensKid Risk, Columbus, Ohio, USA.
Ousmane M DiopGlobal Polio Eradication Initiative, World Health Organization, Geneva, Switzerland.
Mark A PallanschDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
M Steven ObersteDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kimberly M ThompsonKid Risk, Columbus, Ohio, USA.
Centers for Disease Control and Prevention · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectiveTo characterise the costs, including for environmental surveillance (ES), of the Global Polio Laboratory Network (GPLN) that provides laboratory support to the Global Polio Eradication Initiative (GPEI). DESIGN AND

participantsWe conducted a survey of the network across 92 countries of the 146 GPLN laboratories plus three non-GPLN laboratories that concentrate environmental samples to collect information about their activities, characteristics and costs during 2016. We estimate the total costs using regression of reported responses and complementing the findings with GPEI data.

resultsWe received responses from 132 (89%) of the 149 laboratories, with variable response rates for individual questions. We estimate that processing samples of patients with acute flaccid paralysis leads to total costs of approximately $28 million per year (2016 US$) based on extrapolation from reported costs of $16 million, of which 61% were supported by internal (national) funds. Fifty-nine (45%) of the 132 responding laboratories reported supporting ES and we estimate an additional $5.3 million of recurring costs for ES activities performed by the laboratories. The reported costs do not include an estimated additional $10 million of annual global and regional costs to coordinate and support the GPLN. On average, the staff supported by funding for polio in the responding laboratories spent 30% of their time on non-polio activities. We estimate total costs for laboratory support of approximately $43 million (note that this estimate does not include any field or other non-laboratory costs of polio surveillance).

conclusionsAlthough countries contribute significantly to the GPLN financing, many laboratories currently depend on GPEI funds, and these laboratories also support the laboratory component of surveillance activities for other diseases. Sustaining critical global surveillance for polioviruses and transitioning support for other disease programmes will require continued significant funding after polio certification.

Indexed as

International CooperationPoliomyelitisGlobal HealthHumansImmunization ProgramsLaboratoriesPoliovirus VaccinesPublic HealthRisk ManagementSurveys and QuestionnairesPoliovirus Vaccinescosteradicationglobal healthpoliovirussurveillance

Identifiers

PMID30670511
PMCPMC6347914
OpenAlexW2911748741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.